CT Scan to Check Response to First Kidney Cancer Treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses a special CT scan to see how well your first treatment for kidney cancer that has spread is working. It looks at people with clear cell renal cell carcinoma who are starting immunotherapy combined with a targeted drug or two immunotherapy drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with clear cell renal cell carcinoma (a type of kidney cancer).
- Your cancer has spread to other parts of the body (metastatic).
- You have not had any previous treatment for your kidney cancer.
- You are about to start a first-line treatment that includes either immunotherapy plus a targeted drug (IO+TKI) or two immunotherapy drugs (IO+IO).
- You have already had a special CT scan (dual-energy spectral CT) within the last 4 weeks before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
This study is testing whether tracking DNA from your tumor in your blood can help predict how well immunotherapy works for a rare type of kidney cancer called non-clear cell renal cell carcinoma. The goal is to see if this blood test can guide treatment decisions and improve outcomes.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This trial uses two types of PET scans to better target radiation therapy in patients with advanced clear cell kidney cancer that has spread or returned. The goal is to combine radiation with standard drug treatments to improve outcomes.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.